The Effect of Intracameral Triamcinolone Acetonide Injection on the Cornea in Rabbits

Joo Youn Park; Hoon Dong Kim; Kyung Seek Choi

doi:10.3341/jkos.2008.49.4.634

Journal List > J Korean Ophthalmol Soc > v.49(4) > 1008241

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Park, Kim, and Choi: The Effect of Intracameral Triamcinolone Acetonide Injection on the Cornea in Rabbits

Original Article

J Korean Ophthalmol Soc 2008;49(4):634-640.

Published online: 7 September 2008

DOI: https://doi.org/10.3341/jkos.2008.49.4.634

The Effect of Intracameral Triamcinolone Acetonide Injection on the Cornea in Rabbits

Joo Youn Park, M.D., Hoon Dong Kim, M.D., Kyung Seek Choi, M.D.

Department of Ophthalmology, Soonchunhyang University College of Medicine, Seoul, Korea

Address reprint requests to Kyung Seek Choi, M.D. Department of Ophthalmology Soonchunhyang University College of Medicine #657 Hannam-dong, Yongsan-gu, Seoul 140-743, Korea Tel: 82-2-709-9354, Fax: 82-2-798-7797, E-mail: ckseek@naver.com

Received 26 March 2007 Accepted 10 October 2007

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Purpose

To evaluate the safety and effects of intracameral triamcinolone acetonide injection in rabbit corneas.

Methods

Triamcinolone acetonide in the amounts of 0.5, 1, and 2 mg was injected into the anterior chamber of rabbit eyes, and intraocular pressure, corneal thickness, and endothelial cell counts were evaluated on days 1, 3, 7, 14, and 28. Twenty-eight days after triamcinolone acetonide injection, the eyes were enucleated and examined after TUNEL staining.

Results

No statistically significant differences were found among control, 0.5, and 1 mg triamcinolone-injected eyes in central corneal thickness, endothelial cell density, pleomorphism, and polymegathism. There was no difference between 2 mg triamcinolone-injected eyes and control eyes for corneal thickness and cell density, but there were statistically significant differences between these two groups for pleomorphism (p<0.05) and polymegathism (p<0.05).

Conclusions

The results of this study suggested that intracameral injections of 0.5∼1 mg of triamcinolone acetonide are beneficial and cause no toxic effects on corneas.

Keywords: Cornea, Intracameral triamcinolone acetonide injection

References

1. Gordon DM. Prednisone and prednisolone in ocular disease. Am J Ophthalmol. 1956; 41:593–600.

2. Machemer R, Sugita G, Tano Y. Treatment of intraocular proliferations with intravitreal steroids. Trans Am Ophthalmol Soc. 1979; 77:171–80.

3. Kok H, Lau C, Maycock N, et al. Outcome of intravitreal triamcinolone in uveitis. Ophthalmology. 2005; 112:1916.

4. Arevalo JF, Garcia RA, Mendoza AJ. Indocyanine green-mediated photothrombosis with intravitreal triamcinolone acetonide for subfoveal choroidal neovascularization in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2005; 243:1180–5.

5. Chieh JJ, Roth DB, Liu M, et al. Intravitreal triamcinolone acetonide for diabetic macular edema. Retina. 2005; 25:828–34.

6. Cekic O, Chang S, Tseng JJ, et al. Intravitreal triamcinolone injection for treatment of macular edema secondary to branch retinal vein occlusion. Retina. 2005; 25:851–5.

7. Jonas JB, Kreissig I, Degenring RF. Intravitreal triamcinolone acetonide for pseudophakic cystoid macular edema. Am J Ophthalmol. 2003; 136:384–6.

8. Oh J-Y, Wee WR, Lee JH, Kim MK. Short-term effect of intracameral triamcinolone acetonide on corneal endothelium using the rabbit model. Eye. 2007; 21:812–8.

9. Hernaez‐ Ortega MC, Soto‐ Pedre E. Removal of benzyl alcohol from a commercially available triamcinolone acetonide suspension for intravitreal use. Ophthalmic Surg Lasers Imaging. 2006; 37:162–4.

10. Jonas JB, Degenring RF, Kreissig I, et al. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology. 2005; 112:593–8.

11. Chan CK, Fan DS, Chan WM, et al. Ocular-hypertensive response and corneal endothelial changes after intravitreal triamcinolone injections in Chinese subjects: a 6-month follow-up study. Eye. 2005; 19:625–30.

12. Jonas JB, Kreissig I, Degenring RF. Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Ophthalmol. 2003; 87:24–7.

13. Vajpayee RB, Sharma N, Dada T, et al. Management of posterior capsule tears. Surv Ophthalmol. 2001; 45:473–88.

14. Akura J, Hatta S, Kaneda S, et al. Management of posterior capsule rupture during phacoemulsification using the dry technique. J Cataract Refract Surg. 2001; 27:982–9.

15. Yamakiri K, Uchino E, Kimura K, Sakamoto T. Intracameral triamcinolone helps to visualize and remove the vitreous body in anterior chamber in cataract surgery. Am J Ophthalmol. 2004; 138:650–2.

16. Jonas JB. Intraocular availability of triamcinolone acetonide after intravitreal injection. Am J Ophthalmol. 2004; 137:560–2.

17. Chen TY, Yang CM, Liu KR. Intravitreal triamcinolone staining observation of residual undetached cortical vitreous after posterior vitreous detachment. Eye. 2006; 20:423–7.

18. Furino C, Micelli Ferrari T, Boscia F, et al. Triamcinolone-assisted pars plana vitrectomy for proliferative vitreoretinopathy. Retina. 2003; 23:771–6.

19. Walker TD. Benzalkonium toxicity. Clin Experiment Ophthalmol. 2004; 32:657.

20. Morrison VL, Koh HJ, Cheng L, et al. Intravitreal toxicity of the kenalog vehicle (benzyl alcohol) in rabbits. Retina. 2006; 26:339–44.

21. Garcia-Arumi J, Boixadera A, Giralt J, et al. Comparison of different techniques for purification of triamcinolone acetonide suspension for intravitreal use. Br J Ophthalmol. 2005; 89:1112–4.

22. Nishimura A, Kobayashi A, Segawa Y, et al. Isolating triamcinolone acetonide particles for intravitreal use with a porous membrane filter. Retina. 2003; 23:777–9.

23. Foster A, Resnikoff S. The impact of Vision 2020 on global blindness. Eye. 2005; 19:1133–5.

24. Misra A, Burton RL. Incidence of intraoperative complications during phacoemulsification in vitrectomized and nonvitrectomized eyes: prospective study. J Cataract Refract Surg. 2005; 31:1011–4.

25. Mason JO 3rd, Somaiya MD, Singh RJ. Intravitreal concentration and clearance of triamcinolone acetonide in nonvitrectomized human eyes. Retina. 2004; 24:900–4.

26. Zinn KM. Iatrogenic intraocular injection of depot corticosteroid and its surgical removal using the pars plana approach. Ophthalmology. 1981; 88:13–7.

27. Van Horn DL, Sendele DD, Seideman S, Buco PJ. Regenerative capacity of the corneal endothelium in rabbit and cat. Invest Ophthalmol Visual Sci. 1977; 10:597–613.

Figure 1.

Anterior segment photographs after different concentrations of intracameral triamcinolone acetonide injections at 1, 7, and 28 days after 0.5 mg (A, B, C), 1 mg (D, E, F) and 2 mg (G, H, I) triamcinolone acetonide injection into the anterior chamber.

Figure 2.

Specular micrographs at one day after 1 mg (A) and 2 mg (B) triamcinolone acetonide injection; CD=cell density; CV=coefficient of variation; 6A=hexagonality.

Figure 3.

Hematoxylin & eosin staining (A) and TUNEL staining (B) of the central cornea in control, and in rabbit with 0.5, 1, and 2 mg of triamcinolone acetonide injection at 28 days. (×200)

Table 1.

The average corneal thickness (µm) according to triamcinolone acetonide injection dose and time

	Pre-operative	Day 1	Day 3	Day 7	Day 14	Day 28	Statistical significance
BSS (n=5)	342.6±11.7	349.6±20.9	342.6±14.9	354.8±24.0	353.4±19.4	335.2±13.6	NS
TA 0.5 mg (n=5)	324.4±21.2	361.8±17.7	329.4±20.5	360.4±14.2	349.6±30.2	343.0±13.4	NS
TA 1.0 mg (n=5)	348.2±27.1	362.6±15.8	353.8±23.0	358.0±28.6	351.8±28.6	343.2±18.4	NS
TA 2.0 mg (n=5)	337.6±15.6	335.8±9.8	344.8±20.1	351.6±17.6	347.2±24.4	343.6±16.9	NS

Mean±SD (standard deviation); Ta=triamcinolone acetonide; BSS=balanced salt solution; NS=not significant. (p>0.05)

Table 2.

The average corneal endothelial cell density (cell/mm²) according to triamcinolone acetonide injection dose and time

	Pre-operative	Day 1	Day 3	Day 7	Day 14	Day 28	Statistical significance
BSS (n=5)	2941±261	2929±392	2846±201	2903±132	3027±190	2923±223	NS
TA 0.5 mg (n=5)	3028±134	2996±210	2964±100	2929±86	3030±172	2973±126	NS
TA 1.0 mg (n=5)	2978±210	3062±135	2860±213	2928±151	2977±249	2926±234	NS
TA 2.0 mg (n=5)	3006±246	3048±284	2912±197	2871±165	2833±194	2839±188	NS

Mean±SD (standard deviation); Ta=triamcinolone acetonide; BSS=balanced salt solution; NS=not significant. (p>0.05)

Table 3.

The average corneal endothelial polymegathism (coefficient of variation) according to triamcinolone acetonide injection dose and time

	Pre-operative	Day 1	Day 3	Day 7	Day 14	Day 28	Statistical significance
BSS (n=5)	18.0±1.2	22.8±3.4	19.6±4.6	18.2±2.0	18.0±1.5	19.8±3.1	NS
TA 0.5 mg (n=5)	19.4±0.8	25.0±5.7	21.2±3.9	20.2±3.2	20.5±2.4	20.2±4.2	NS
TA 1.0 mg (n=5)	21.0±1.8	27.4±5.5	21.4±4.0	22.0±3.2	21.4±2.8	19.8±2.6	NS
TA 2.0 mg (n=5)	19.8±1.3	37.0±4.8	26.0±3.1	21.4±2.0	21.8±2.2	20.8±2.9	P=0.007^* P=0.02^†

Mean±SD (standard deviation); TA=triamcinolone acetonide; BSS=balanced salt solution; NS=not significant (p>0.05)

^* Test of within-subject (time)

^† Test of between-subjects (concentration).

Table 4.

The average corneal endothelial pleomorphism (%， hexagonality) according to triamcinolone acetonide injection dose and time

	Pre-operative	Day 1	Day 3	Day 7	Day 14	Day 28	Statistical significance
BSS (n=5)	67.6±7.9	72.6±4.9	72.2±3.8	72.0±4.1	70.6±3.9	71.2±3.1	NS
TA 0.5 mg (n=5)	66.6±6.9	72.8±7.4	68.8±4.4	68.8±3.2	69.0±1.7	69.4±2.0	NS
TA 1.0 mg (n=5)	67.6±8.0	68.6±4.5	68.6±6.1	69.0±6.2	70.4±5.3	68.6±4.2	NS
TA 2.0 mg (n=5)	70.0±11.0	57.8±5.4	61.6±4.8	63.8±3.4	63.4±3.8	69.6±4.8	P=0.036^* P=0.02^†

Mean±SD (standard deviation); TA=triamcinolone acetonide; BSS=balanced salt solution; NS=not significant (p>0.05)

^* Test of within-subject (time)

^† Test of between-subjects (concentration).

TOOLS

Similar articles